CME Group (CME) Stock Looks Expensive After An 81% Five Year Run
CME Group has delivered a strong 80.5% return over the past 5 years, yet current valuation checks suggest the stock is trading at a premium to what its fundamentals imply. Both the Excess Returns intrinsic value estimate and market multiple comparisons point to the shares looking expensive rather than like a clear bargain right now.
- The 80.5% 5 year return highlights that CME Group has already rewarded long term holders, which can limit how much additional upside is priced in today.
- Growth in futures and options product breadth, including new equity factor, commodity and wind power contracts, may support expectations for future cash flows, while ongoing regulatory friction around prediction markets and crypto linked products could add uncertainty to how those cash flows evolve.
- CME Group carries a low value score of 2, which indicates that on the broader set of valuation checks the stock leans expensive rather than offering clear value.
For investors, the debate is whether CME Group's current share price already reflects the benefits of its product expansion and regulatory positioning, leaving limited room for valuation driven gains.
Spot 44 high quality undervalued stocks that pair CME Group style market exposure with valuations that currently look more restrained.Is CME Group Getting Expensive on Excess Returns?
The Excess Returns model looks at how much value CME Group is estimated to create above its cost of equity over time, based on future profitability on its book of assets.
For CME Group, the model uses a Book Value of $73.82 per share and a Stable EPS of $13.58 per share, both anchored in analyst estimates for future returns on equity. The implied Average Return on Equity of 16.13% compares with a Cost of Equity of $6.69 per share, which yields an estimated Excess Return of $6.89 per share and a Stable Book Value of $84.19 per share. Together, these inputs translate into an intrinsic value estimate of $246.65 per share.
Against the current share price, this Excess Returns estimate points to the stock trading about 15.9% above intrinsic value, so CME Group screens as overvalued on this method. The recent White House crypto summit, which reinforced a push toward tighter federal oversight of digital assets and prediction markets, helps explain why investors may be paying up for CME Group’s regulated futures infrastructure even as the model suggests a premium valuation.
On the Excess Returns model, CME Group looks overvalued, with the current price sitting noticeably above the estimated intrinsic value.
Our Excess Returns analysis suggests CME Group may be overvalued by 15.9%. Discover 44 high quality undervalued stocks or create your own screener to find better value opportunities.
Does CME Group Look Pricey on Earnings?
P/E is a useful yardstick for CME Group because earnings are a key focus for investors in mature market infrastructure businesses. CME Group currently trades on a P/E of 24.1x, which sits below the Capital Markets industry average of 38.6x and also below the peer group average of 27.3x.
However, the tailored fair P/E ratio for CME Group is 16.2x. This reflects what the multiple might look like once you factor in its profitability profile, size, sector and risk characteristics. The current 24.1x level sits clearly above this fair ratio. As a result, while CME Group does not appear stretched versus the broad industry, it still prices in a premium relative to what the model suggests is justified for the stock.
On the P/E multiple, CME Group screens as overvalued compared with its modelled fair ratio, even though it trades below the wider industry average.
See what the numbers say about this price — find out in our valuation breakdown.
The CME Group Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for CME Group pick up where this valuation puzzle leaves off. They spell out which combinations of growth, margins and earnings would need to play out for CME Group's stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Each one links its number to a clear view on how growth, profitability and risk could develop, which you can revisit as fresh information emerges.
Use the Narratives tool to add your own number driven view on CME Group, including whether the recent crypto summit focus and new contract launches support today's pricing, and see how that thesis tracks as fresh news lands. Add your voice to the Simply Wall St community and set out a clear, data based case that you can revisit over time.
Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!
The Bottom Line
CME Group screens as overvalued on both the Excess Returns intrinsic value estimate and the tailored P/E multiple, which point in the same direction. The broader valuation checks are also weak, so there is not a clear counter signal to offset those models. From here, the key question is whether CME Group can deliver the kind of earnings resilience and product traction that keeps investors comfortable paying this premium rather than seeing the valuation settle closer to the modelled fair levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com